カテゴリ： Allied Market Research, 世界, 医療/バイオ

乳がん治療薬のグローバル市場（2023-2032）：化学療法、ホルモン療法、標的療法、免疫療法

■ 英語タイトル：Breast Cancer Drugs Market By Therapy (Chemotherapy, Hormonal therapy, Targeted therapy, Immunotherapy), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2023-2032

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23SEP146）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23SEP146
■ 発行日：2023年5月
■ 調査対象地域：グローバル
■ 産業分野：生命科学
■ ページ数：252
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[乳がん治療薬のグローバル市場（2023-2032）：化学療法、ホルモン療法、標的療法、免疫療法]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

乳がん治療薬の市場規模は2022年に264億ドル、2032年には593億ドルに達すると推定され、2023年から2032年までの年平均成長率は8.4%です。乳がんは、乳房組織に発生するがんの一種です。乳房の細胞が制御不能に増殖・分裂し、腫瘍を形成することで発症します。これらの腫瘍は、悪性（がん性）のものと良性（非がん性）のものがあります。主に女性に発生しますが、比較的まれですが男性にも発生することがあります。乳管、小葉（乳汁を分泌する）、結合組織など、乳房のさまざまな部位から発生する可能性があります。乳管に発生する最も一般的な乳がんは乳管がんと呼ばれ、小葉に発生するがんは小葉がんと呼ばれます。また、乳がんの治療は、化学療法、分子標的治療、ホルモン療法など、さまざまなアプローチを組み合わせて行います。各治療法は、乳がんの管理と闘病において特定の目的を果たすものであり、治療法の選択は、乳がんの病期とタイプ、特定の受容体の存在、患者の全体的な健康状態や嗜好など、さまざまな要因によって決まります。

乳がん治療薬市場の成長を促進する主な要因は、乳がんの有病率の上昇、診断技術の進歩、乳がんと利用可能な治療オプションに関する認知度の向上です。乳がんは世界的な健康問題であり、世界中の何百万人もの女性に影響を及ぼしています。乳がんの罹患率は年々着実に上昇しており、女性の間で最も罹患率の高いがんの1つとなっています。例えば、世界保健機関（WHO）2021によると、2020年には世界で約230万人の女性が乳がんと診断されており、乳がんの有病率の上昇が市場の成長を促進すると予想されています。また、乳がんの予後を改善するには、早期発見・早期診断が不可欠です。定期的な乳房自己検診、乳房臨床検査、マンモグラフィ検診は、治療が最も効果的な乳がんを早期に発見するのに役立ちます。このように、乳がんの早期発見のための診断技術の進歩は、市場の成長を後押しすると予想されます。

さらに、乳がん罹患率の上昇に伴い、乳がん患者の治療オプションの改善に注目が集まっています。その目的は、生存率を高めるだけでなく、副作用を最小限に抑え、患者の生活の質を向上させる薬剤を開発することです。このような治療選択肢の改善への意欲は、製薬企業や研究者がより効果的で忍容性の高い乳がん治療薬の開発に投資することを促し、市場の成長を後押ししています。さらに、乳がんやその危険因子、定期的な検診の重要性に関する意識の高まりにより、乳がん検診を受ける女性の数が増加しています。さらに、政府のイニシアチブ、非営利団体、医療キャンペーンが、女性の意識を高め、定期的なマンモグラムや臨床検査を受けるよう促す上で重要な役割を果たしています。検診率の上昇は早期診断を促進し、乳がん治療薬の需要急増につながるため、市場の成長を促進します。

しかし、薬剤に伴う副作用などの要因が市場の成長を抑制すると予想されています。乳がん治療薬の多くは、患者のQOLに影響を与える副作用や毒性を伴います。例えば、化学療法は脱毛、吐き気、疲労、免疫抑制などの副作用を引き起こすことで知られており、市場の成長を阻害しています。さらに、乳がん治療のための新規治療薬に対する需要の増加、より効果的な新薬開発のための研究開発活動の増加、抗がん剤に対する規制当局の承認の増加は、乳がん治療薬市場の主要プレーヤーに有利な機会を提供すると期待されています。

乳がん治療薬市場は、治療法、年齢層、流通チャネル、地域によって区分されます。治療法ベースでは、市場は化学療法、ホルモン療法、標的療法、免疫療法に分類されます。年齢層別では、市場は55歳未満と55歳以上に二分されます。流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他LAMEA）で分析されます。
世界の乳がん治療薬市場で事業を展開する主な主要企業は、ギリアド・サイエンシズ社、ノバルティス社、ファイザー社、アストラゼネカ社、イーライリリー・アンド・カンパニー社、メルク社、ブリストル・マイヤーズ スクイブ社、ザイダスライフサイエンス社、テバ・ファーマシューティカル・インダストリーズ社、F.ホフマン・ラ・ロシュ社です。主要企業は、製品ポートフォリオを拡大するために買収、資金調達、製品上市、製品承認などの戦略を採用しています。

ステークホルダーにとっての主なメリット
本レポートは、2022年から2032年までの乳がん治療薬市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、乳がん治療薬の市場機会を特定します。
主な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
乳がん治療薬市場のセグメンテーションを詳細に分析し、市場機会を把握します。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
地域別および世界の乳がん治療薬市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主要市場セグメント
治療法別
化学療法
ホルモン療法
標的療法
免疫療法

年齢層別
55歳未満
55歳以上

販売チャネル別
病院薬局
ドラッグストア・小売薬局
オンラインプロバイダー

地域別
北米
米国
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主な市場プレイヤー
○ Merck & Co., Inc.
○ Zydus Lifesciences Limited
○ Gilead Sciences, Inc.
○ Novartis AG
○ Eli Lilly and Company
○ AstraZeneca plc
○ Bristol-Myers Squibb Company
○ F. Hoffmann-La Roche Ltd.
○ Teva Pharmaceutical Industries Ltd.
○ Pfizer Inc.

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：乳がん治療薬市場、治療法別
第5章：乳がん治療薬市場、年齢層別
第6章：乳がん治療薬市場、流通チャネル別
第7章：乳がん治療薬市場、地域別
第8章：競争状況
第9章：企業情報

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of breast cancer
3.4.1.2. Advancements in diagnostic technologies
3.4.1.3. High investments in research and development

3.4.2. Restraints
3.4.2.1. Adverse effects associated with the use cancer drugs

3.4.3. Opportunities
3.4.3.1. High growth potential in untapped emerging economies

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: BREAST CANCER DRUGS MARKET, BY THERAPY
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Hormonal therapy
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Targeted therapy
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Immunotherapy
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: BREAST CANCER DRUGS MARKET, BY AGE GROUP
5.1. Overview
5.1.1. Market size and forecast
5.2. Below 55 years
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Above 55 years
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug Store and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: BREAST CANCER DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Therapy
7.2.3. Market size and forecast, by Age group
7.2.4. Market size and forecast, by Distribution channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Therapy
7.2.5.1.3. Market size and forecast, by Age group
7.2.5.1.4. Market size and forecast, by Distribution channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Therapy
7.2.5.2.3. Market size and forecast, by Age group
7.2.5.2.4. Market size and forecast, by Distribution channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Therapy
7.2.5.3.3. Market size and forecast, by Age group
7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Therapy
7.3.3. Market size and forecast, by Age group
7.3.4. Market size and forecast, by Distribution channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Therapy
7.3.5.1.3. Market size and forecast, by Age group
7.3.5.1.4. Market size and forecast, by Distribution channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Therapy
7.3.5.2.3. Market size and forecast, by Age group
7.3.5.2.4. Market size and forecast, by Distribution channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Therapy
7.3.5.3.3. Market size and forecast, by Age group
7.3.5.3.4. Market size and forecast, by Distribution channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Therapy
7.3.5.4.3. Market size and forecast, by Age group
7.3.5.4.4. Market size and forecast, by Distribution channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Therapy
7.3.5.5.3. Market size and forecast, by Age group
7.3.5.5.4. Market size and forecast, by Distribution channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Therapy
7.3.5.6.3. Market size and forecast, by Age group
7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Therapy
7.4.3. Market size and forecast, by Age group
7.4.4. Market size and forecast, by Distribution channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Therapy
7.4.5.1.3. Market size and forecast, by Age group
7.4.5.1.4. Market size and forecast, by Distribution channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Therapy
7.4.5.2.3. Market size and forecast, by Age group
7.4.5.2.4. Market size and forecast, by Distribution channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Therapy
7.4.5.3.3. Market size and forecast, by Age group
7.4.5.3.4. Market size and forecast, by Distribution channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Therapy
7.4.5.4.3. Market size and forecast, by Age group
7.4.5.4.4. Market size and forecast, by Distribution channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Therapy
7.4.5.5.3. Market size and forecast, by Age group
7.4.5.5.4. Market size and forecast, by Distribution channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Therapy
7.4.5.6.3. Market size and forecast, by Age group
7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Therapy
7.5.3. Market size and forecast, by Age group
7.5.4. Market size and forecast, by Distribution channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Therapy
7.5.5.1.3. Market size and forecast, by Age group
7.5.5.1.4. Market size and forecast, by Distribution channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Therapy
7.5.5.2.3. Market size and forecast, by Age group
7.5.5.2.4. Market size and forecast, by Distribution channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Therapy
7.5.5.3.3. Market size and forecast, by Age group
7.5.5.3.4. Market size and forecast, by Distribution channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Therapy
7.5.5.4.3. Market size and forecast, by Age group
7.5.5.4.4. Market size and forecast, by Distribution channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Novartis AG
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Pfizer Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. AstraZeneca plc
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Eli Lilly and Company
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Merck & Co., Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Bristol-Myers Squibb Company
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Zydus Lifesciences Limited
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Teva Pharmaceutical Industries Ltd.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. F. Hoffmann-La Roche Ltd.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Gilead Sciences, Inc.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments

LIST OF TABLES
TABLE 01. GLOBAL BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 02. BREAST CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 03. BREAST CANCER DRUGS MARKET FOR HORMONAL THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 04. BREAST CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 05. BREAST CANCER DRUGS MARKET FOR IMMUNOTHERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 07. BREAST CANCER DRUGS MARKET FOR BELOW 55 YEARS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. BREAST CANCER DRUGS MARKET FOR ABOVE 55 YEARS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 10. BREAST CANCER DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 11. BREAST CANCER DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 12. BREAST CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. BREAST CANCER DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA BREAST CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 18. U.S. BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 19. U.S. BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 20. U.S. BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. CANADA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 22. CANADA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 23. CANADA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. MEXICO BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 25. MEXICO BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 26. MEXICO BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 27. EUROPE BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 28. EUROPE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 29. EUROPE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 30. EUROPE BREAST CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 31. GERMANY BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 32. GERMANY BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 33. GERMANY BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. FRANCE BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 35. FRANCE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 36. FRANCE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 37. UK BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 38. UK BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 39. UK BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. ITALY BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 41. ITALY BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 42. ITALY BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 43. SPAIN BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 44. SPAIN BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 45. SPAIN BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 53. JAPAN BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 54. JAPAN BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 55. JAPAN BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. CHINA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 57. CHINA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 58. CHINA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 59. INDIA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 60. INDIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 61. INDIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 71. LAMEA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 72. LAMEA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 73. LAMEA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 74. LAMEA BREAST CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 75. BRAZIL BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 76. BRAZIL BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 77. BRAZIL BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 87. NOVARTIS AG: KEY EXECUTIVES
TABLE 88. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 89. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 90. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 91. NOVARTIS AG: KEY STRATERGIES
TABLE 92. PFIZER INC.: KEY EXECUTIVES
TABLE 93. PFIZER INC.: COMPANY SNAPSHOT
TABLE 94. PFIZER INC.: PRODUCT SEGMENTS
TABLE 95. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 96. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 97. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 98. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 99. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 100. ASTRAZENECA PLC: KEY STRATERGIES
TABLE 101. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 102. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 103. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 104. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 105. ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 106. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 107. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 108. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 109. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 110. MERCK & CO., INC.: KEY STRATERGIES
TABLE 111. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 112. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 113. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 114. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 115. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 116. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 117. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 118. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 119. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES
TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 123. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 125. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 126. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 127. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 128. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 129. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 130. GILEAD SCIENCES, INC.: KEY EXECUTIVES
TABLE 131. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 132. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
TABLE 133. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 134. GILEAD SCIENCES, INC.: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 転移性がん治療薬のグローバル市場（2023-2032）：化学療法、ホルモン療法、標的療法、免疫療法
  • がん治療薬のグローバル市場2023-2027：標的療法、免疫療法、ホルモン療法、化学療法
  • 抗がん剤の世界市場2022：化学療法、標的療法、免疫療法、ホルモン療法（生物療法）、その他
  • がん用個別化医療のグローバル市場展望 2023年-2029年：免疫療法、標的療法、化学療法、ホルモン療法、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23SEP146 )"乳がん治療薬のグローバル市場（2023-2032）：化学療法、ホルモン療法、標的療法、免疫療法" (英文：Breast Cancer Drugs Market By Therapy (Chemotherapy, Hormonal therapy, Targeted therapy, Immunotherapy), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2023-2032)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。